Corpus Intelligence IC Memo — PROVIDENCE ALASKA MEDICAL CENTER 2026-04-26 06:37 UTC
IC Memo — PROVIDENCE ALASKA MEDICAL CENTER
Investment Committee Memorandum | AK | 401 beds | Grade B | EBITDA uplift $54.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PROVIDENCE ALASKA MEDICAL CENTER

CCN 020001 | nan, AK | 401 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

PROVIDENCE ALASKA MEDICAL CENTER is a 401-bed safety-net/medicaid heavy in nan, AK with $741.2M in net patient revenue and a 6.8% operating margin. The hospital serves a payer mix of 31.9% Medicare, 40.5% Medicaid, and 27.6% commercial.

Thesis: Platform Growth. Our ML models identify $54.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 6.8% to 14.2% (+736bps).

Net Revenue HCRIS$741.2M
Current EBITDA COMPUTED$50.3M
Operating Margin COMPUTED6.8%
Occupancy HCRIS76.9%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS25.8%
Distress Probability ML50.7%

2. Market Context & Competitive Position

24
AK Hospitals
-2.1%
State Median Margin
1166
Comparable Hospitals

AK has 24 Medicare-certified hospitals with a median operating margin of -2.1%. The target's margin of 6.8% places it above the state median. Among 1166 size-comparable peers (200-802 beds), the median margin is -3.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (200-802), prioritizing same-state peers. 1166 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PROVIDENCE ALASKA MEDICAL CENT (Target)AK401$741.2M6.8%
ST. LUKES HOSPITALPA633$8.94B87.9%
STANFORD HEALTH CARECA657$6.76B3.7%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
STRONG MEMORIAL HOSPITALNY749$3.31B5.2%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
UCSD MEDICAL CENTERCA718$3.06B-7.2%
UNIVERSITY OF NORTH CAROLINA HNC799$2.88B13.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $54.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$15.6M+210bp18mo
Cost to Collect4.5%2.5%$14.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$14.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$9.0M+122bp9mo
Clean Claim Rate88.0%96.0%$474K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$15.6M
Cost to Collect
$14.8M
Denial Rate Reduction
$14.7M
A/R Days Reduction
$9.0M
Clean Claim Rate
$474K
Total EBITDA Uplift$54.6M
Current EBITDA$50.3M
+ RCM Uplift+$54.6M
Pro Forma EBITDA$104.9M
Current Margin6.8%
Pro Forma Margin14.2%
WC Released (1x)$28.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$77.4M$877.6M11.33x62.5%
Base (11x exit)10.0x11.0x$77.4M$990.5M12.79x66.5%
Bull Case9.0x11.0x$69.7M$1.20B17.16x76.6%
Bull (12x exit)9.0x12.0x$69.7M$1.32B19.01x80.2%
Bear Case11.0x10.0x$85.2M$579.7M6.80x46.8%
Bear (11x exit)11.0x11.0x$85.2M$665.3M7.81x50.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (40.5%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 50.7% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 1166 hospitals with 200-802 beds
  • Same-state prioritization (n=1)
  • Comp margins: P25=-13.2% / P50=-3.8% / P75=5.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.